About Us

Advanced BioHealing (ABH)

Advanced BioHealing (ABH) was founded in 2003 to develop and commercialize a next-generation bioengineered tissue product. By 2005 two rounds of venture financing totaling $10.4 million had been raised to help fund product development. During this time ABH operated as a truly virtual company with two full-time employees and a collection of consultants performing various tasks.

In late 2005, when U.K. based Smith & Nephew announced the sale of assets related to their bioengineered tissue business, the opportunity to purchase these products (Dermagraft & TransCyte) seemed to fit perfectly with the ABH strategy. The most intriguing aspect was that both products were already approved for sale in the U.S. (and a number of other countries) thus providing ABH an “instant” commercial opportunity. The challenge was that manufacturing and promotion of the products had already been stopped.

After evaluating the commercial opportunity and tasks for re-starting manufacturing it was clear there were many reasons to purchase the global rights to these outstanding products and the decision was taken to proceed. The deal was finalized in May, 2006.

Once the agreement was signed, the original 60,000 square-foot manufacturing facility in La Jolla California was renovated, revalidated and began manufacturing Dermagraft again. During this time a new commercial team was also put in place for the U.S. market. The first pieces of ABH-manufactured Dermagraft were shipped to U.S. customers on February 15, 2007.

Also in the first quarter of 2007 a Series C round of financing composed of $30 million in venture investment and $10 million in venture debt was finalized. This capital has enabled the Company to build a fully integrated operation with research, manufacturing and commercial capabilities.

Today ABH has more than 120 employees committed to producing and distributing Dermagraft, a break-through product for the treatment of diabetic foot ulcers. In addition to current efforts related to Dermagraft, the Company continues to evaluate out-license and in-license opportunities to expand its role as one of the premier regenerative medicine companies in the world.

For more information about Dermagraft click on this link,
visit www.Dermagraft.com or call ABH customer service
at 1-877-DERMAGRAFT (1-877-337-6247)